PMID- 32363334
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210208
IS  - 2589-790X (Electronic)
IS  - 2589-790X (Linking)
VI  - 2
IP  - 4
DP  - 2020 Jul
TI  - Cardiovascular Collapse in COVID-19 Infection: The Role of Venoarterial 
      Extracorporeal Membrane Oxygenation (VA-ECMO).
PG  - 273-277
LID - 10.1016/j.cjco.2020.04.003 [doi]
AB  - Coronavirus Disease 2019 (COVID-19) has been associated with cardiovascular 
      complications, including acute cardiac injury, heart failure, and cardiogenic 
      shock (CS). The role of venoarterial extracorporeal membrane oxygenation 
      (VA-ECMO) in the event of COVID-19-associated cardiovascular collapse has not 
      been established. We reviewed the existing literature surrounding the role of 
      VA-ECMO in the treatment of coronavirus-related cardiovascular collapse. COVID-19 
      is associated with a higher incidence of cardiovascular complications compared 
      with previous coronavirus outbreaks (Severe Acute Respiratory Syndrome 
      Coronavirus and Middle East Respiratory Syndrome Coronavirus). We found only 1 
      case report from China in which COVID-19-associated fulminant myocarditis and CS 
      were successfully rescued using VA-ECMO as a bridge to recovery. We identified 
      potential clinical scenarios (cardiac injury, myocardial infarction with and 
      without obstructive coronary artery disease, viral myocarditis, and decompensated 
      heart failure) leading to CS and risk factors for poor/uncertain benefit (age, 
      sepsis, mixed/predominantly vasodilatory shock, prothrombotic state or 
      coagulopathy, severe acute respiratory distress syndrome, multiorgan failure, or 
      high-risk prognostic scores) specific to using VA-ECMO as a bridge to recovery in 
      COVID-19 infection. Additional considerations and proposed recommendations 
      specific to the COVID-19 pandemic were formulated with guidance from published 
      data and expert consensus. A small subset of patients with cardiovascular 
      complications from COVID-19 infection may progress to refractory CS. While 
      accepting that resource scarcity may be the overwhelming concern for healthcare 
      systems during this pandemic, VA-ECMO can be considered in highly selected cases 
      of refractory CS and echocardiographic evidence of biventricular failure. The 
      decision to initiate this therapy should take into consideration the availability 
      of resources, perceived benefit, and risks of transmitting disease.
CI  - (c) 2020 Canadian Cardiovascular Society. Published by Elsevier Inc.
FAU - Chow, Justin
AU  - Chow J
AD  - Division of Cardiology, Department of Medicine, McMaster University, Hamilton, 
      Ontario, Canada.
FAU - Alhussaini, Anhar
AU  - Alhussaini A
AD  - Division of Cardiology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - College of Medicine, King Saud bin Abdulaziz University for Health Sciences, 
      Jeddah, Saudi Arabia.
FAU - Calvillo-Arguelles, Oscar
AU  - Calvillo-Arguelles O
AD  - Division of Cardiology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Peter Munk Cardiac Centre, Ted Rogers Center for Heart Research, University 
      Health Network, Toronto, Ontario, Canada.
FAU - Billia, Filio
AU  - Billia F
AD  - Division of Cardiology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Peter Munk Cardiac Centre, Ted Rogers Center for Heart Research, University 
      Health Network, Toronto, Ontario, Canada.
AD  - Medical Director, Mechanical Circulatory Support Program, Peter Munk Cardiac 
      Centre, University Health Network, Toronto, Ontario, Canada.
FAU - Luk, Adriana
AU  - Luk A
AD  - Division of Cardiology, Department of Medicine, University of Toronto, Toronto, 
      Ontario, Canada.
AD  - Peter Munk Cardiac Centre, Ted Rogers Center for Heart Research, University 
      Health Network, Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200408
PL  - United States
TA  - CJC Open
JT  - CJC open
JID - 101763635
CIN - J Cardiothorac Vasc Anesth. 2021 Mar;35(3):703-706. PMID: 33288430
CIN - J Cardiothorac Vasc Anesth. 2021 Mar;35(3):707-710. PMID: 33288431
PMC - PMC7194983
EDAT- 2020/05/05 06:00
MHDA- 2020/05/05 06:01
PMCR- 2020/04/08
CRDT- 2020/05/05 06:00
PHST- 2020/03/28 00:00 [received]
PHST- 2020/04/04 00:00 [accepted]
PHST- 2020/05/05 06:00 [pubmed]
PHST- 2020/05/05 06:01 [medline]
PHST- 2020/05/05 06:00 [entrez]
PHST- 2020/04/08 00:00 [pmc-release]
AID - S2589-790X(20)30043-3 [pii]
AID - 10.1016/j.cjco.2020.04.003 [doi]
PST - epublish
SO  - CJC Open. 2020 Apr 8;2(4):273-277. doi: 10.1016/j.cjco.2020.04.003. eCollection 
      2020 Jul.